Update on AIN

It is a great honor to have been awarded the third position of the JLGTD 2023 Edward J. Wilkinson Best Paper Award with the paper "A**l Intraepithelial Neoplasia and A**l Squamous Cell Carcinoma: Updates From the Last 3 Years."

I will also be presenting this paper on an online session at the 2024 American Society for Colposcopy and Cervical Pathology (ASCCP) anual Meeting.

Predictors of treatment and follow-up for a**l precancers.

The other side of screening: predictors of treatment and follow-up for a**l precancers in a large health system - PubMed Even in large specialized a**l cancer screening programs adherence to HSIL treatment and surveillance is low. Psychosocial and economic determinants of health may impact retention in care. Addressing both personal and structural barriers to patient engagement may improve the effectiveness of a**l ca...

Important study on home-based self-collection of cells for a**l cancer screening. Protocol published on BMJ Open.

Rationale and design of the Prevent A**l Cancer Self-Swab Study: a protocol for a randomised clinical trial of home-based self-collection of cells for a**l cancer screening - PubMed NCT03489707.

Vulvar neoplasia as a risk factor for a**l cancer.

Vulvar High-Grade Squamous Intraepithelial Lesions and Cancer as a Risk Factor for A**l Cancer: A Review - PubMed Clinicians need be aware that women with vHSIL and VSCC comprise one of the highest-risk groups for ASCC. Inquiring suggestive symptoms of ASCC and a digital anorectal examination can help in the early detection of this type of cancer.

IPVC 2021 Special Interest Satellite Symposium 12: A**l cancer and precancerous lesions: what´s new?

Conference Calendar - The 34th International Papillomavirus Conference The title of the BD Symposium will be, “Screening Smarter in the Post-Pandemic Era: The Clinical Utility of Extended Genotyping and Self-Collection”. The moderator, Marie-Hélène Mayrand, MD, PhD, FRCSC of the Université de Montréal will introduce the symposium and the three symposium speaker...

Suboptimal immunogenicity of HPV vaccine in solid organ transplant recipients.

Immunogenicity and Safety of the 9-Valent Human Papillomavirus Vaccine in Solid Organ Transplant Recipients and Adults Infected With Human Immunodeficiency Virus (HIV) - PubMed Immunogenicity of the 9vHPV vaccine is high in persons living with HIV but suboptimal in SOT recipients. The vaccine is safe and well tolerated in both groups.

A landmark study.

Epidemiology of a**l human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled a**lysis of 64 studies - PubMed International Agency for Research on Cancer.

A new meta-a**lysis published on AIDS journal evaluating high-risk HPV, HSIL and cancer in a**l condylomas.
Patients with a history of a**l condylomas have a high risk of a**l cancer. The prevalence of high-risk HPV and precancerous lesions in a**l condylomas from immunocompromised patients is high.

High-risk hpv, precancerous lesions and cancer in a**l condylomas: systematic review and meta-a**lysis - PubMed patients with a history of a**l condylomas have a high risk of a**l SCC, especially men. The prevalence of HR-HPV and HSIL in condylomas from immunocompromised patients is high. This information can change patient follow-up and treatment.

The number of cases of a**l cancer is lower in HIV-patients on an a**l cancer screening program.

Routine Screening of A**l Cytology in Persons With Human Immunodeficiency Virus and the Impact on Invasive A**l Cancer: A Prospective Cohort Study - PubMed The number of cases of IASCC was significantly lower in persons with HIV engaged in an a**l cytology screening program. These results should be validated in a randomized clinical trial.

https://www.europeancancer.org/topic-networks/1:hpv-action.html

Focused Topic Networks EU Commissioner for Health and Food Safety, Stella Kyriakides, presents the elimination of cancers caused by human papillomavirus (HPV) as one of the Flagship initiatives of Europe’s Beating Cancer Plan during the event: United against Cancer on 3 February 2021. The panel discussi...

HPV vaccination might not provide benefit on HIV-infected adults aged ≥27 years to prevent new a**l HPV infections or to improve a**l precancerous lesions outcomes.

A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298 - PubMed NCT01461096.

https://www.friendsofendoscopy.org/podcasts

Podcasts ​Dr Andreia Albuguerque from Lisbon discusses her paper on the neglected topic of a**l cancer recently published in Lancet Gastroenterology and Hepatology 2021;6:327-34 . As larger endoscopy units...